FSE$FMS

Fresenius Medical Care AG & Co. KGAA · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Fresenius Medical Care reported modest revenue growth and a significant decline in net income in Q4 2024.

Fresenius Medical Care posted Q4 2024 revenue of €5.09 billion, reflecting a 2% year-over-year increase. Operating income fell 39% to €259 million due to portfolio optimization impacts, while net income dropped 64% to €67 million. The Care Enablement segment drove growth, increasing revenue by 11%, while Care Delivery revenue declined by 1% due to divestitures. Free cash flow improved by 25% to €599 million, supporting deleveraging efforts.

  • Total revenue grew 2% year-over-year to €5.09 billion, led by the Care Enablement segment.
  • Operating income declined 39% to €259 million due to one-time portfolio optimization effects.
  • Net income dropped 64% to €67 million, impacted by lower operating profit and restructuring costs.
  • Free cash flow increased by 25% to €599 million, supporting financial deleveraging efforts.

Headline financials

Total Revenue

$5.28B

Previous: $5.37B-1.6%
EPS (adj)

$0.95

Previous: $0.47+100.4%
Operating Margin

5.1%

No prior period
Free Cash Flow Margin

11.8%

No prior period
Net Income

$66.9M

Previous: $188M-64.4%
Operating Income

$259M

Previous: $439M-40.9%
Gross Profit

$1.27B

Previous: $1.35B-5.9%

Revenue & EPS history

Fresenius Medical Care · Revenue · Quarterly

$5.28B

Q4 2024-1.6%vs Q4 2023
Beat estimate in 7 of 16 quarters(44%)
ActualEstimate

Forward guidance

Fresenius Medical Care expects low single-digit revenue growth and high-teens to high-twenties percent earnings growth in 2025.

Tailwinds

  • Revenue growth expected to be positive in the low-single-digit range.
  • Operating income projected to grow in the high-teens to high-twenties percent range.
  • FME25 transformation program savings target raised to €750 million.
  • Care Enablement expected to continue strong volume growth momentum.
  • Further deleveraging expected with continued strong cash generation.

Headwinds

  • Portfolio optimization may continue to weigh on short-term revenue growth.
  • Higher personnel and operational costs could pressure operating margins.
  • Unfavorable foreign exchange impacts may create headwinds on earnings.
  • Ongoing restructuring costs associated with transformation initiatives.
  • Potential uncertainties in reimbursement rates and regulatory changes.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.1%

Avg return

Earnings day

-1.3%

Avg return

5 days after

+0.2%

Avg return

30 days after

16%

11 / 67 earnings

Positive

+23.1%

Q1 2011

Best reaction

-8.9%

Q1 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-6.7%-1.3%+55.7%
Q4 2024+0.0%+3.9%+5.3%
Q2 2024+0.0%-6.4%-4.9%
Q4 2023+6.7%-8.2%-9.7%
Q3 2023+0.0%+2.0%+24.6%
Q2 2023+0.0%+0.2%-7.9%
Q1 2023-0.5%+1.3%+0.2%
Q4 2022+6.9%+0.0%+1.6%
Q3 2022+0.0%+7.9%+11.3%
Q2 2022+0.0%-18.6%-24.4%
Q1 2022-8.9%-4.7%-9.3%
Q4 2021+0.0%-2.1%-2.5%
Q3 2021-4.6%+4.3%-10.8%
Q2 2021+0.0%-3.2%-5.7%
Q1 2021+0.0%-1.0%+3.6%
Q4 2020+0.0%-3.1%+3.5%
Q3 2020+0.0%-2.5%+6.5%
Q2 2020+0.0%-4.9%-9.2%
Q1 2020+0.0%+2.9%+13.6%
Q4 2019+3.1%-4.2%-28.6%
Q3 2019+3.3%+10.5%+10.8%
Q2 2019-8.8%-10.1%-11.5%
Q1 2019+6.7%-1.8%-12.6%
Q4 2018+0.0%+3.8%+0.5%
Q3 2018-1.9%-2.8%+4.0%
Q2 2018+0.0%+0.9%+8.3%
Q1 2018+0.0%-2.5%-3.6%
Q4 2017-2.5%-5.8%-6.7%
Q3 2017-0.5%+0.2%+2.6%
Q2 2017+0.0%-1.3%-0.1%
Q1 2017+0.0%+1.5%+6.7%
Q4 2016+0.0%+0.8%+1.8%
Q3 2016+0.0%+0.5%-2.5%
Q2 2016+2.6%+1.0%-4.5%
Q1 2016-3.1%
Q4 2015+1.1%
Q3 2015+5.4%
Q2 2015-4.7%
Q1 2015+0.0%
Q4 2014+7.0%
Q3 2014+0.0%
Q2 2014-4.5%
Q1 2014+0.0%
Q4 2012-6.4%
Q4 2013-6.4%
Q3 2013+0.0%
Q2 2013-3.7%
Q1 2013+0.0%
Q3 2012+0.0%
Q2 2012+0.0%
Q1 2012-0.6%
Q4 2011+1.4%
Q3 2011+0.0%
Q2 2011+0.0%
Q1 2011+23.1%
Q4 2010+0.0%
Q3 2010+0.0%
Q2 2010+0.0%
Q1 2010+0.0%
Q1 2009+0.0%
Q4 2009+0.0%
Q4 2007+0.0%
Q3 2008+0.0%
Q3 2009+0.0%
Q2 2008+0.0%
Q4 2008+0.0%
Q2 2009+0.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro